Novo Nordisk has entered a multiyear research collaboration with biotech startup Replicate Bioscience, focusing on self-replicating RNA (srRNA) technology to develop novel therapies for obesity, type 2 diabetes, and cardiometabolic conditions. The agreement provides Replicate with research funding and up to $550 million in milestone payments plus royalties. Novo gains exclusive global licensing rights to Replicate’s srRNA platform. This partnership enhances Novo's early-stage pipeline beyond current GLP-1 agents and represents a strategic investment amid recent leadership changes and market pressures. Replicate’s technology aims to harness patients' cells to produce therapeutic proteins more durably than traditional RNA methods, potentially overcoming limitations of existing treatments.